HOPE summit keynote now on YouTube - enjoy. www.youtube.com/watch?v=UMNY...
HOPE Summit 2026 Keynote -- Hope 2026: Wagons Roll
YouTube video by LUNGevityFoundation
youtube.com
Sanjay Popat
@drsanjaypopat.bsky.social
Thoracic Oncologist, Royal Marsden Hospital | Professor, Institute of Cancer Research | Past chair, British Thoracic Oncology Group | Views are my own
www.sciencedirect.com/science/arti... Now in press in Journal of Thoracic Oncology - a hypothesis I’ve presented at meetings for a couple of years but never put in writing before.
Hiding in Plain Sight: The Neuro-Protective Benefit of Tyrosine Kinase Inhibition in Non–Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers
sciencedirect.com
Pleased to publish a case report exploring a number of interesting elements of ERBB2 (HER2) mutated NSCLC on @jtoonline.bsky.social with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social www.jtocrr.org/article/S266...
Acquired ERBB2 amplification and overexpression as on-target resistance mechanisms to zongertinib with subsequent response to trastuzumab deruxtecan; a case report
A number of drugs are in development for the treatment of ERBB2(HER2)-mutated Non-Small Cell Lung Cancer (NSCLC) including antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and ty...
jtocrr.org
pubmed.ncbi.nlm.nih.gov/41609978/ Delighted to explore the complex landscape of EGFRm NSCLC in 2026 with @drsanjaypopat.bsky.social and @dralexiusjohn.bsky.social Mechanisms of resistance FLAURA vs MARIPOSA vs FLAURA 2 Decision making after these regimens Genomic informed and agnostic approaches
Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer - PubMed
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been standard of care as monotherapy for EGFR-mutated advanced non-small cell lung cancer since reporting of the FLAURA phase III clinical trial, which demonstrated superiority over first-generatio …
pubmed.ncbi.nlm.nih.gov
There’s a lot going on and new in #lungcancer. Be there to understand the latest developments!
ESMO - European Society for Medical Oncology@myesmo.bsky.social · 8mo ago📣 Registration for #ELCC26 is open! Join us in Copenhagen, 25–28 March, for cutting-edge science and global networking. ⏰ Early rates until 21 Jan. 🔗 https://ow.ly/mAHv50XBJQL Don’t miss your chance to shape the future of #LungCancer care!
Fellows, writing a manuscript with me? The 10 golden rules never grow old
For those of you wondering why newer antibodies are now called -tugs -barts -migs and -ments not -mabs, this is the official @who.int INN explainer tinyurl.com/49bxfn4t
🌍 Why do people who’ve never smoked get lung cancer? Our first session dives into epidemiology, environmental aetiology, and early detection. With @ruthstraussfdn.bsky.social 🧠 #BTOG2025 | 📍 London | 📅 13 Nov 🔗 www.btog.org/non-smo... #LungCancer #LCSM #NonSmokingLungCancer
The #ASCO25 #OncoAlertTOP10 Abstracts in #LungCancer 🫁 These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸 @biagioricciutimd.bsky.social @stephenvliu.bsky.social @drsanjaypopat.bsky.social Ping @drjnaidoo.bsky.social
Thank you #LCS2025 in #KualaLumpur 🇲🇾 for hosting an informative & interactive lung cancer meeting! Always pleasure to meet colleagues who are keen to move our 🫁 field forward. #LCSM @apoddc @APCLC_2023 @stephanieplsaw @drdaviddwlee #BeungChulAhn #PJVoon #JenniferLeong @drsanjaypopat.bsky.social
❗️FLAURA2 approved by NICE❗️ Already on BlueTeq! Now an option for 1L EGFR+ pts Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen
BTOG@btog.bsky.social · last yr.NICE has recommended Osimertinib with pemetrexed and platinum-based chemotherapy (based on the FLAURA2 trial) as an option for untreated advanced NSCLC in adults whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Great to see this important step for our EGFR mutant patients: FLAURA-2 approval by NICE. Interesting to note that the reimbursement (Blueteq form) allows a single cycle of chemo if clinically urgently indicated, but no access if PD on adjuvant osi. @btog.bsky.social @egfrpositiveuk.bsky.social
BTOG@btog.bsky.social · last yr.BTOG wishes to inform members of a new NICE release that has been published today. Full details www.nice.org.uk/guidance/ind...
Very important dataset and a set forward to potential ambulatory delivery in the future.
Dr. Herbert Loong@herbloongmd.bsky.social · last yr.Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀 doi.org/10.1016/j.es...
HER2 mutated NSCLC increasingly important as a rest of new TKI show promising effectiveness in early phase trials Riyaz Shah and I discuss these, and other HER2 targeted treatments
BTOG@btog.bsky.social · last yr.New Podcast Alert! BTOG Does ... HER2. Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .
Very nice perspective from Drs Tannock, De Vries & colleagues @pmresearch-uhn.bsky.social in @thelancetoncol.bsky.social on dose optimization for oncology drugs: an area that @nihr.bsky.social should be evaluating, IMHO @nhsengland.bsky.social @bopa.org.uk shorturl.at/aszUO
Dose optimisation to improve access to effective cancer medicines
Access to many cancer medicines on WHO's Essential Medicines List (EML) is restricted because of price, especially in low-income and middle-income countries (LMICs). Other cancer medicines that have b...
shorturl.at
Was really looking forward to this session and it didn't disappoint! Always find related questions the hardest to answer in clinic. Just a shame they had the graveyard slot! @bopa.org.uk take note of the speakers, they would be great additions to annual conference agenda #BTOG25
Well #BTOG25 that’s a wrap for 2025 from #Belfast Thanks to @btog.bsky.social for 3 fantastic years in Belfast It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏 Here’s to next year in Edinburgh! @drsanjaypopat.bsky.social @tnewsomdavis.bsky.social
With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25
Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social! @btog.bsky.social #BTOG25
Carles Escriu@carlesescriu.bsky.social · last yr.SCLC was indeed the star at #BTOG25. Looking forward to the benefit (and challenges) of novel therapeutic strategies. Translational studies to aid patient selection will now be more needed than ever.
@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS #BTOG25
Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM
At #BTOG25 & I tringied by Matt’s comment on the fact that GP practices who request more chest X-rays have less stage III/IV #lungcaner disease? Read more here! www.respiratoryfutures.org.uk/features/dia...
Diagnosing Lung Cancer: X-rays & CT Scans | Respiratory Futures
Learn how chest x-rays and CT scans aid in diagnosing lung cancer and the role of primary care in early detection.
respiratoryfutures.org.uk
We really need to make sure people know this!! It’s never too late to quit smoking. Treating tobacco dependence is cancer treatment! We would not let this survival benefit pass us by of this was a new oncology drug. #BTOG25
Chloe Waterson@chloewaterson.bsky.social · last yr.So what's the point in quitting smoking once you've already been diagnosed with cancer? Quitting in the first 6 months could add extra years to survival! #BTOG25
So what's the point in quitting smoking once you've already been diagnosed with cancer? Quitting in the first 6 months could add extra years to survival! #BTOG25
@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25
@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25
Small cell in never smokers. On the rise for unknow reasons and a different biology. Having recently encountered my first patient who’s a never smoker(and no alcohol or recreational drugs), with extensive stage disease this insight is fascinating @stephenvliu.bsky.social #BTOG25
We are delighted to announce that the 2025 BTOG Lifetime Achievement Award has been presented to Professor Cindy Billingham. The announcement was made by Professor Gary MIddleton and hosted at the 23nd BTOG Annual Conference in Belfast by Professor @drsanjaypopat.bsky.social #BTOG25 #LCSM
